Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active Crohns disease, a long-term and progressive intestinal condition. This Phase 3 study aims to assess how well these treatments work by measuring clinical and endoscopic remission at Week 48. The study is sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to receive either JNJ-78934804 or guselkumab, both given as subcutaneous injections. Treatment starts with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks from Week 12 onward. Those meeting rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, then continue maintenance dosing from Week 28. After completing the double-blind phase at Week 48, participants who may benefit can join a long-term extension phase. During the study, participants will undergo assessments to measure clinical remission, endoscopic remission, and other outcomes like deep remission and corticosteroid-free remission at various time points. Researchers will monitor patient-reported outcomes, adverse events, and serious adverse events for up to approximately three years. The study involves regular evaluations of disease activity and safety to understand treatment effects and participant well-being over time.
Actively Recruiting
Researchers are evaluating the efficacy and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active ulcerative colitis, a chronic condition causing inflammation and ulcers in the colon lining. This phase 3, randomized, double-blind, active-controlled study aims to assess how well these treatments work by measuring clinical remission at Week 48. Participants receive either JNJ-78934804 or guselkumab through subcutaneous injections. Both treatments begin with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks starting at Week 12. Participants who meet rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, with maintenance continuing every 4 weeks from Week 28. Those completing the initial 48-week treatment phase and deemed to benefit may join a long-term extension phase. Throughout the study, participants undergo assessments including endoscopic evaluations, clinical remission status, symptom scores, quality of life questionnaires, and safety monitoring for adverse events up to approximately 3 years. The primary outcome is the percentage of participants achieving clinical remission at Week 48, with multiple secondary outcomes measured at various time points. This comprehensive evaluation helps understand the treatment effects and safety profile over time.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of TAR-210 compared to intravesical chemotherapy in treating high-risk non-muscle-invasive bladder cancer HR-NMIBC. This Phase 3 study focuses on disease-free survival, which is the length of time participants live without signs or symptoms of cancer returning or worsening. The study targets patients with specific FGFR genetic alterations who have previously received BCG treatment but remain at high risk for cancer recurrence. Participants are randomly assigned to one of two groups Group A will have the investigational drug TAR-210 placed inside the bladder on Day 1 and continue treatment for about two years. Group B will receive intravesical chemotherapy with either mitomycin C or gemcitabine weekly for 4 to 6 doses, followed by monthly maintenance for up to one year, with an optional second year of maintenance depending on the investigators decision. All treatments are delivered directly into the bladder. Throughout the study, participants will have regular assessments including monitoring for cancer recurrence, progression, and overall survival for up to five years. Researchers will collect safety data such as adverse events and changes in laboratory tests and vital signs. Quality of life will be measured using specific questionnaires at multiple time points. The study involves ongoing visits and evaluations to closely observe treatment effects and participant well-being over the long term.
Actively Recruiting
Researchers are comparing the disease-free survival in adults with intermediate-risk non-muscle invasive bladder cancer IR-NMIBC who receive either TAR-210 or the investigators choice of intravesical chemotherapy. The study focuses on participants with susceptible FGFR alterations and aims to evaluate the efficacy and safety of these treatments over approximately four years. This is a phase 3 randomized trial sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to one of two groups. Group A receives TAR-210, which is inserted into the bladder on Day 1 and removed after 12 weeks this procedure is repeated every 12 weeks for about one year. Group B receives intravesical chemotherapy with mitomycin C MMC or gemcitabine, chosen by the investigator. Chemotherapy is given once weekly for 4 to 6 doses, followed by a maintenance phase lasting at least 6 months and up to one year. Throughout the study, participants undergo multiple cystoscopies and tissue assessments to monitor for recurrence or progression of bladder cancer. Researchers measure disease-free survival, time to next treatment, recurrence-free survival, progression-free survival, adverse events, overall survival, and quality of life using standardized questionnaires. Safety is monitored from the first dose through 30 days after the last dose. The total participation period spans about four years and two months for comprehensive evaluation.